Effect of Silybin on Lipid Profile in Hypercholesterolaemic Rats

• Main Authors: Senthil Gobalakrishnan, Sylvia Santhakumari Asirvatham, Venkatraman Janarthanam
• Format: Article
• Language: English
• Published: JCDR Research and Publications Private Limited 2016-04-01
• Series: Journal of Clinical and Diagnostic Research
• Subjects: coronary heart disease; hyperlipidemia; siliphos
• Online Access: https://jcdr.net/articles/PDF/7566/16393_CE[Ra1]_F(GH)_PF1(Ro_Om)_PFA(AK)_PF2(PAG).pdf

Introduction: Hyperlipidemia is a major cause of atherosclerosis and atherosclerosis associated conditions, such as Coronary Heart Disease (CHD), ischaemic cerebrovascular disease and peripheral vascular disease. Though there are hypolipidemic drugs available, the search for a more efficacious hypo lipidemic agent was always going on. Aim: To study the effect of Silybin on lipid profile in Hypercholesterolaemic rats. Materials and Methods: After grant of permission from animal ethics committee, the animals were divided into four groups of eight each (normal control, Experimental control with High cholesterol diet, High cholesterol diet + Silybin 300mg, High cholesterol diet + Silybin 600mg). At the end of 60 days the animals in all the groups were subjected to overnight fasting followed by plasma and liver biochemical analyses. Statistical Analysis: The data were analysed by ANNOVA followed by Duncan’s multi range test and the value of p≤0.05 was used as the criterion for statistical significance. Results: The rats fed on high cholesterol diet showed significant increase in serum total cholesterol, Triglycerides, LDL-C and VLDL-C. Treatment with Silybin significantly decreased serum total cholesterol (24%), Triglycerides (21%), LDL-C (24%) in a dose dependent manner. Rats treated with Silybin (300 and 600 mg/kg) showed significant increase in hepatic HDL –C and decrease in other lipid profiles. Conclusion: Treatment with Silybin significantly decreased both serum and hepatic total cholesterol, triglycerides, VLDL-C, LDL-C and increased HDL-C at both doses.